Showing results (261-270 of 296) with videos related to

Sort By:
Pageof 30
Cancer Letters|February 22, 2019
Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphataseIacopo Gesmundo, Laura Di Blasio, Dana Banfi, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 21, 2007
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditionsCarlotta Gauna, Rosalie M Kiewiet, Joop A M J L Janssen, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2012
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDYA J van der Lely, Beverly M K Biller, Thierry Brue, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2017
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter StudyAndrea Giustina, Gherardo Mazziotti, Salvatore Cannavò, et al.
Diabetes|March 14, 2014
RFamide peptides 43RFa and 26RFa both promote survival of pancreatic β-cells and human pancreatic islets but exert opposite effects on insulin secretionRiccarda Granata, Fabio Settanni, Letizia Trovato, et al.
Molecular and Cellular Endocrinology|May 2, 2006
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptorCarlotta Gauna, Patric J D Delhanty, Maarten O van Aken, et al.
European Journal of Endocrinology|October 17, 2018
Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDYMichael Buchfelder, Aart-Jan van der Lely, Beverly M K Biller, et al.
The Journal of Clinical Endocrinology and Metabolism|May 3, 2025
Reassessing the role of copeptin in emergency department admissions for hypotonic hyponatremiaAlessandro Maria Berton, Emanuele Varaldo, Marco Zavattaro, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2019
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesotheliomaTania Villanova, Iacopo Gesmundo, Valentina Audrito, et al.
Frontiers in Neuroscience|April 6, 2023
Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo studyAlessandro Maria Berton, Mirko Parasiliti-Caprino, Nunzia Prencipe, et al.
Pageof 30